Enliven Therapeutics Inc.
Ownership
Ownership Structure
Who owns Enliven Therapeutics Inc. (ELVN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.6% of the shares are freely tradable; institutional investors hold 89.7%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Orbimed Advisors LLC | 10.86 | 7,959,538 | +0.0 | 03/31/2026 |
| FMR Inc | 9.32 | 6,829,246 | -3.9 | 03/31/2026 |
| Polar Capital Holdings PLC | 6.91 | 5,065,933 | +44.2 | 03/31/2026 |
| BlackRock Inc | 5.03 | 3,684,707 | +2.0 | 03/31/2026 |
| COMMODORE CAPITAL LP | 4.47 | 3,275,000 | -30.2 | 03/31/2026 |
| Vestal Point Capital LP | 4.44 | 3,250,000 | -15.1 | 03/31/2026 |
| Bellevue Group AG | 3.17 | 2,320,867 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.96 | 2,168,162 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Polar Capital Healthcare Opports Inc | 4.93 | 3,610,672 | +0.0 | 07/31/2026 |
| Polar Capital Biotech S Inc | 3.49 | 2,555,889 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Kunkel Lori Anne | Director | 41,884 | 2,102,577 $ | Jul 6, 2026 | direct |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | 40,036 | 2,009,807 $ | Aug 17, 2026 | direct |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | 25,000 | 1,255,000 $ | Aug 17, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,388 | 59.35 | 82,383 |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 4,630 | 58.35 | 270,168 |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,100 | 59.35 | 65,281 |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3,900 | 58.37 | 227,650 |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Other | 5,000 | 2.48 | 12,400 |
| Aug 4, 2026 | Derynck Mika K | Director | Sell | 158,795 | 60.21 | 9,561,587 |
| Aug 4, 2026 | Derynck Mika K | Director | Other | 20,491 | 22.47 | 460,433 |
| Aug 4, 2026 | Derynck Mika K | Director | Other | 23,364 | 14.85 | 346,955 |
| Aug 4, 2026 | Derynck Mika K | Director | Other | 27,567 | 25.28 | 696,894 |
| Aug 4, 2026 | Derynck Mika K | Director | Other | 87,373 | 2.48 | 216,685 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 123 | 53.87 | 6,626 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,638 | 53.38 | 140,823 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,564 | 52.32 | 134,143 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 369 | 51.48 | 18,997 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 324 | 49.97 | 16,191 |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Other | 1,072 | 2.48 | 2,659 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 63 | 53.92 | 3,397 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,184 | 53.42 | 116,669 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,063 | 52.39 | 108,085 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 459 | 51.55 | 23,660 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 231 | 50.05 | 11,563 |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Other | 5,000 | 2.48 | 12,400 |
| Jul 6, 2026 | Kunkel Lori Anne | Director | Sell | 5,889 | 50.84 | 299,421 |
| Jul 6, 2026 | Kunkel Lori Anne | Director | Sell | 4,111 | 49.98 | 205,482 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.